The Na ؉ :K ؉ :2Cl ؊ cotransporter (NKCC2) is the target of loop diuretics and is mutated in Bartter's syndrome, a heterogeneous autosomal recessive disease that impairs salt reabsorption in the kidney's thick ascending limb (TAL). Despite the importance of this cation/chloride cotransporter (CCC), the mechanisms that underlie its regulation are largely unknown. Here, we show that intracellular chloride depletion in Xenopus laevis oocytes, achieved by either coexpression of the K-Cl cotransporter KCC2 or low-chloride hypotonic stress, activates NKCC2 by promoting the phosphorylation of three highly conserved threonines (96, 101, and 111) in the amino terminus. Elimination of these residues renders NKCC2 unresponsive to reductions of [Cl ؊ ]i. The chloride-sensitive activation of NKCC2 requires the interaction of two serine-threonine kinases, WNK3 (related to WNK1 and WNK4, genes mutated in a Mendelian form of hypertension) and SPAK (a Ste20-type kinase known to interact with and phosphorylate other CCCs). WNK3 is positioned upstream of SPAK and appears to be the chloridesensitive kinase. Elimination of WNK3's unique SPAK-binding motif prevents its activation of NKCC2, as does the mutation of threonines 96, 101, and 111. A catalytically inactive WNK3 mutant also completely prevents NKCC2 activation by intracellular chloride depletion. Together these data reveal a chloride-sensing mechanism that regulates NKCC2 and provide insight into how increases in the level of intracellular chloride in TAL cells, as seen in certain pathological states, could drastically impair renal salt reabsorption.ion transport ͉ loop of Henle ͉ protein serine-threonine kinases ͉ hypertension ͉ diuretics
Melanoma represents approximately 4% of human skin cancers, yet accounts for approximately 80% of deaths from cutaneous neoplasms (1). Although progress has been made in understanding the genetics of the molecular events underlying melanoma oncogenesis (2-4), the clinical challenge remains enormous. A genetic hallmark of melanoma is the presence of activating mutations in the oncogenes BRAF and NRAS, which are present in 70% and 15% of melanomas, respectively, and lead to constitutive activation of mitogen-activated protein kinase pathway signaling (3,5). However, molecules that inhibit mitogen-activated protein kinase pathway-associated kinases, like BRAF and MEK, have shown only limited efficacy in the treatment of metastatic melanoma (6). Thus, a deeper understanding of the cross talk between signaling networks and the complexity of melanoma progression should lead to more effective therapy.Hedgehog (HH) signaling is controlled at the cell surface by two transmembrane proteins, the tumor suppressor Patched-1 (PTCH1), which acts as a HH receptor, and the oncoprotein Smoothened (SMO). In the absence of HH, PTCH1 maintains SMO in an inactive state. In the presence of any of the three HH ligands (Sonic, Indian, or Desert HH), inhibition of SMO by PTCH1 is alleviated and a signal is transduced that leads to the nuclear translocation and activation of GLI family transcription factors (7,8). GLIs are often overexpressed in cancers and contribute to the progression of a variety of neoplasms via regulation of cell cycle progression and apoptosis (9,10). One recent study (11) Article
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.